dc.creatorFerreira, Helen
dc.creatorMendes, Mayara Abud
dc.creatorBarbosa, Mayara Garcia de Mattos
dc.creatorOliveira, Eliane Barbosa de
dc.creatorSales, Anna Maria
dc.creatorMoraes, Milton Ozório
dc.creatorSarno, Euzenir Nunes
dc.creatorPInheiro, Roberta Olmo
dc.date2022-02-08T14:47:22Z
dc.date2022-02-08T14:47:22Z
dc.date2021
dc.date.accessioned2023-09-26T21:53:12Z
dc.date.available2023-09-26T21:53:12Z
dc.identifierFERREIRA, Helen et al. Potential Role of CXCL10 in Monitoring Response to Treatment in Leprosy Patients. Frontiers in Immunology, v. 12, Article 662307, p. 1 - 10, July 2021.
dc.identifier1664-3224
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/51075
dc.identifier10.3389/fimmu.2021.662307
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8873936
dc.descriptionThe treatment of multibacillary cases of leprosy with multidrug therapy (MDT) comprises 12 doses of a combination of rifampicin, dapsone and clofazimine. Previous studies have described the immunological phenotypic pattern in skin lesions in multibacillary patients. Here, we evaluated the effect of MDT on skin cell phenotype and on the Mycobacterium leprae-specific immune response. An analysis of skin cell phenotype demonstrated a significant decrease in MRS1 (SR-A), CXCL10 (IP-10) and IFNG (IFN-g) gene and protein expression after MDT release. Patients were randomized according to whether they experienced a reduction in bacillary load after MDT. A reduction in CXCL10 (IP-10) in sera was associated with the absence of a reduction in the bacillary load at release. Although IFN-g production in response to M. leprae was not affected by MDT, CXCL10 (IP-10) levels in response to M. leprae increased in cells from patients who experienced a reduction in bacillary load after treatment. Together, our results suggest that CXCL10 (IP-10) may be a good marker for monitoring treatment efficacy in multibacillary patients.
dc.formatapplication/pdf
dc.languageeng
dc.publisherFrontiers Media
dc.rightsopen access
dc.subjectHanseníase
dc.subjectCélulas da pele
dc.subjectTerapia multidrogas
dc.subjectIFN-y
dc.subjectCXCL-10
dc.subjectLeprosy
dc.subjectSkin cells
dc.subjectIFN-y
dc.subjectCXCL-10
dc.subjectMultidrug therapy
dc.titlePotential Role of CXCL10 in Monitoring Response to Treatment in Leprosy Patients
dc.typeArticle


Este ítem pertenece a la siguiente institución